Kaneoka, A.; Okada, E.; Sugino, H.; Saito-Sasaki, N.; Omoto, D.; Nakamura, M.
Vedolizumab Attenuates Immune-Checkpoint-Therapy-Induced Infliximab-Refractory Colitis. Diagnostics 2022, 12, 480.
https://doi.org/10.3390/diagnostics12020480
AMA Style
Kaneoka A, Okada E, Sugino H, Saito-Sasaki N, Omoto D, Nakamura M.
Vedolizumab Attenuates Immune-Checkpoint-Therapy-Induced Infliximab-Refractory Colitis. Diagnostics. 2022; 12(2):480.
https://doi.org/10.3390/diagnostics12020480
Chicago/Turabian Style
Kaneoka, Ayaka, Etsuko Okada, Hitomi Sugino, Natsuko Saito-Sasaki, Daisuke Omoto, and Motonobu Nakamura.
2022. "Vedolizumab Attenuates Immune-Checkpoint-Therapy-Induced Infliximab-Refractory Colitis" Diagnostics 12, no. 2: 480.
https://doi.org/10.3390/diagnostics12020480
APA Style
Kaneoka, A., Okada, E., Sugino, H., Saito-Sasaki, N., Omoto, D., & Nakamura, M.
(2022). Vedolizumab Attenuates Immune-Checkpoint-Therapy-Induced Infliximab-Refractory Colitis. Diagnostics, 12(2), 480.
https://doi.org/10.3390/diagnostics12020480